Syndax Pharmaceuticals Current Valuation vs. Gross Profit

1T3 Stock  EUR 12.30  0.20  1.65%   
Based on Syndax Pharmaceuticals' profitability indicators, Syndax Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Syndax Pharmaceuticals' ability to earn profits and add value for shareholders.
For Syndax Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Syndax Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Syndax Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Syndax Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Syndax Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Syndax Pharmaceuticals Gross Profit vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15CUGDNNE6UZSL1T3 020M40M60M80M100M120M140M160M 0200M400M600M800M1B
Syndax Pharmaceuticals is the top company in current valuation category among its peers. It also is number one stock in gross profit category among its peers fabricating about  0.14  of Gross Profit per Current Valuation. The ratio of Current Valuation to Gross Profit for Syndax Pharmaceuticals is roughly  7.01 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Syndax Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Syndax Current Valuation vs. Competition

Syndax Pharmaceuticals is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 1.93 Billion. Syndax Pharmaceuticals totals roughly 979.72 Million in current valuation claiming about 51% of stocks in Biotechnology industry.

Syndax Gross Profit vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Syndax Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
979.72 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Syndax Pharmaceuticals

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
139.71 M
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Syndax Gross Profit Comparison

Syndax Pharmaceuticals is currently under evaluation in gross profit category among its peers.

Syndax Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Syndax Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Syndax Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Syndax Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Syndax Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Syndax Pharmaceuticals operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 38 people.

Syndax Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Syndax Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Syndax Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Syndax Pharmaceuticals' important profitability drivers and their relationship over time.

Use Syndax Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Syndax Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Syndax Pharmaceuticals Pair Trading

Syndax Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Syndax Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Syndax Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Syndax Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Syndax Pharmaceuticals to buy it.
The correlation of Syndax Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Syndax Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Syndax Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Syndax Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Syndax Pharmaceuticals position

In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Asset Management Thematic Idea Now

Asset Management
Asset Management Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Asset Management theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Management Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Syndax Stock

When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:
Check out Trending Equities.
For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
To fully project Syndax Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Syndax Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Syndax Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Syndax Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Syndax Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Syndax Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Syndax Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.